Colonic capsule endoscopy (CCE) is an emerging diagnostic tool for evaluating the large intestine. Initially introduced in 2006 and improved with second-generation devices in 2009, CCE provides a noninvasive, painless alternative to colonoscopy. Despite early limitations such as cost, bowel preparation, and inability to perform biopsies, the COVID-19 pandemic highlighted its value as a remote, pain-free diagnostic modality. CCE is increasingly recognized for its accuracy in detecting colorectal cancer and polyps, with studies demonstrating higher detection rates compared to computed tomography colonography (CTC) for lesions ≥6 mm and ≥ 10 mm. Guidelines from the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) and the US Multi-Society Task Force on Colorectal Cancer (CRC) support CCE in specific scenarios, including incomplete colonoscopies, patients refusing colonoscopy, or as an adjunct in Fecal Immunochemical Test (FIT)-positive screening. Recent studies indicate promising applications in first-degree relatives of CRC patients and symptomatic or surveillance patients, although bowel preparation and completion rates remain challenges. Ongoing advancements in technology and bowel cleansing protocols may expand CCE’s utility, including potential panenteric exploration. CCE’s role in CRC screening, surveillance, and specific clinical scenarios is growing, with expectations of broader adoption as evidence and technology evolve.